Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Where from here?
View:
Post by WarrantOfficer on Mar 04, 2021 8:54am

Where from here?

Great that we have 2 HC approvals. Where does this get us? Management must keep the momenteum moving forward. Do not want the stock to slide as this will jepordize any future financing. IMO, three key take aways from their website Voyageur Deck Nov 2020 

Voyageur and ThinQ in negotiations with Indian Contract Manufacturing Companies to begin immediate sales in the Indian market for iodine products - Sales targeted for 2021. When in 2021?

FDA applications for barium contrast will be filed with use of proceeds from financing: • Consultants in place. • FDA waiving fees on first product application - an update on FDA applications?

AVL Calgary facility to produce barium contrast, marketing and sales - renovations and upgrades were scheduled for completion the end of Jan 2021 and are supply lines pre-established?
Comment by postie1 on Mar 04, 2021 7:22pm
Good questions. Considering on the TSX Venture got slaughtered today (-6.62%) I think we held up pretty well.  We should be a growth/defensive play once this gets going.
Comment by truckulater1 on Mar 05, 2021 1:35am
Except for UCO, nothing but a sea of red in me stocks.  I don't think we are going anywhere for a bit.  Up a couple pennies, down a couple pennies.  Health Canada approving more will move it a bit, but nothing huge IMHO.  News on approval from FDA will  shoot it up like a firwork thinggy.  Best bet is to use this dawdlin time to get s'more.  I got 10K the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1